Abstract
Background: Endothelial injury occurring during cardiopulmonary bypass is a major contributing
factor in the development of organ dysfunction, which leads to many of the postoperative
complications occurring during cardiac surgery.
Objective: This narrative review aims to summarize the main mechanisms of cardiopulmonary bypass -
related disease, evaluating the unfavorable events leading to tissue injury, with a description of current
pharmacologic and non-pharmacologic mechanisms to reduce CPB-related injury.
Methods: A Medline/Pubmed/Scopus search was conducted using clinical queries with the key terms
"cardiac surgery", “cardiopulmonary bypass”, "inflammation" and “endothelial injury”, and related
MeSH terms, until July 2019. The search strategy included meta-analyses, randomized controlled trials,
clinical trials, reviews and pertinent references. Patents were searched using the same key terms from
https://patents.google.com/, www.uspto.gov, and www.freepatentsonline.com.
Results: In this review, we discuss the current knowledge of the mechanisms of vascular endothelial
cell injury, the acute inflammatory response, and the regulatory factors that control the extent of vascular
injury during extracorporeal circulation, summarizing the main target of anti-inflammatory pharmacologic
and non-pharmacologic strategies.
Conclusion: Inflammatory response and endothelial dysfunction following cardiopulmonary bypass are
the prices to pay for the benefits offered during cardiac surgery procedures. Counteracting the detrimental
effect of extracorporeal circulation appears to be crucial to improve clinical outcomes in pediatric
and adult cardiac surgery. The intrinsic complexity and the tight interplay of the factors involved
might require a holistic approach against inflammation and endothelial response.
Keywords:
Cardiac surgery, cardiopulmonary bypass, cytokine scavenger, endothelial dysfunction, extracorporeal circulation,
glycocalyx, inflammation, neuromodulation.
[95]
Egan JR, Butler TL, Cole AD, Aharonyan A, Baines D, Street N, et al. Myocardial ischemia is more important than the effects of cardiopulmonary bypass on myocardial water handling and postoperative dysfunction: a pediatric animal model. J Thorac Cardiovasc Surg 2008; 136: 1265-73.
[129]
Abrahamov D. Compositions and methods for treating postoperative
complications of cardiopulmonary surgery. US Application
US20160089423 (2016), WO2016071761 (2016) &
US20170354722 (2017).
[130]
Summar ML, Barr FE. Intravenous administration of citrulline
during surgery. US Application US20160374972 (2016) &
WO2017004233 (2017)
[131]
Borow K, Travis DW. Methods for performing a coronary artery
bypass graft procedure. EP3100739 (2016).
[132]
Salzman AL, Jagtap P, Southan GJ. Substituted 1-
pyrrolidinyloxy, 1-piperidinyloxy and 1-azepanyloxy compounds
for treating diseases associated with oxidative stress or endothelial
dysfunction. US9604932 (2017).
[133]
Salzman AL, Jagtap P, Southan GJ. Method for treating diseases
associated with oxidative stress or endothelial dysfunction.
US20170327466 (2017).
[134]
Jay GD, Sullivan BD, Schmidt TA, et al. Use of PRG4 as an anti-inflammatory agent. WO2016123123
(2016) & US20180015141 (2018).
[135]
Pollard B. Cardiac glycosides to treat cystic fibrosis and other IL-8
dependent disorders. US20140187505 (2014).
[142]
Levine JA, Faltys MA. Single-pulse activation of the cholinergic
anti-inflammatory pathway to treat chronic inflammation
US8788034 (2014).
[143]
Levine JA, Faltys MA. Extremely low duty-cycle activation of
the cholinergic anti-inflammatory pathway to treat chronic inflammation.
US9211410 (2015) & US9849286 (2018).
[144]
Tracey KJ, Rosas-Ballina M. Methods and systems for reducing
inflammation by neuromodulation of T-cell activity. US9211409
(2015).
[145]
Tracey KJ, Rosas-Ballina M, Faltys MA, Zitnik RJ. Methods
and systems for reducing inflammation by neuromodulation and
administration of an anti-inflammatory drug. US9662490 (2017).
[146]
Bright C. Systems and methods for sympathetic cardiopulmonary
neuromodulation. WO2016176333 (2016) & US9855317 (2018).
[147]
Moss J, Lingen M, Singleton PA, Garcia JGN. Use of opioid
antagonists to attenuate endothelial cell proliferation and migration.
US9662390 (2017).
[148]
Johansson P, Ostrowski SR. Compounds capable of modulating/
preserving endothelial integrity for use in prevention or treatment
of acute traumatic coagulopathy and resuscitated cardiac arrest.
US20150057325 (2015).
[149]
Johansson P, Ostrowski SR. Methods of treating and preventing
endothelial dysfunction using bardoxolone methyl or analogs
thereof. US20150080465 (2015).
[150]
Chin MPH, Meyer CJ. Methods of treating and preventing
endothelial dysfunction using bardoxolone methyl or analogs
thereof. US20150080465 (2015).
[151]
Chin MPH, Meyer CJ. Methods of treating and preventing
endothelial dysfunction using bardoxololone methyl or analogs
thereof. WO2015027206 (2015).